Evidence map›Paper›PMID 37093656›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2023

CD4 Effector TCR Avidity for Peptide on APC Determines the Level of Memory Generated.

Michael C Jones, Catherine Castonguay, Padma P Nanaware, Grant C Weaver, Brian Stadinski, Olivia A Kugler-Umana, Eric S Huseby, Lawrence J Stern, Karl Kai McKinstry, Tara M Strutt and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. CD301bNature communications · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Michael C JonesDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0002-5986-5426
Catherine CastonguayDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.
Padma P NanawareDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.
Grant C WeaverDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0003-1151-2944
Brian StadinskiDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.
Olivia A Kugler-UmanaDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.
Eric S HusebyDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.
Lawrence J SternDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0001-9870-8557
Karl Kai McKinstryDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL.ORCID 0000-0002-5038-7229
Tara M StruttDivision of Immunity and Pathogenesis, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL.ORCID 0000-0002-4465-1783
Priyadharshini DevarajanDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0003-2058-6339
Susan L SwainDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0002-3643-8018
University of Massachusetts Chan Medical School · USUniversity of Central Florida · US

Funding

T cell and transgenic core U19AI109858 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HUSEBY, ERIC S · 2014 to 2018
$11.9M
TRAINING IN IMMUNOLOGY (COMPETITIVE RENEWAL OF AI07439)T32AI007349 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J. · 1989 to 2024
$4.5M
TCR signaling control of thymic Treg selection and immune homeostasisR01AI143976 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BERG, LESLIE JOAN, HUSEBY, ERIC S · 2020 to 2024
$2.9M
Defining a memory checkpoint for CD4 T cellsR01AI118820 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SWAIN, SUSAN L · 2015 to 2019
$2.1M
Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infectionR01AI165406 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI STRUTT, TARA MARLENE · 2021 to 2025
$1.9M
Training in the Molecular Basis of Autoimmunity and AutoinflammationT32AI132152 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Katherine A. Fitzgerald, Ann Marshak-Rothstein · 2018 to 2026
$1.6M
Maintaining Robust T Cell Immunity For Broad Protection Against InfluenzaR21AI146532 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SWAIN, SUSAN L · 2019 to 2020
$461k
Harnessing Age-Associated B cells for a Universal Influenza Vaccine for the AgedR21AI173593 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SWAIN, SUSAN L · 2023 to 2024
$461k
Impact of TcR Signal Strength at the Effector Checkpoint on Protective CD4 T Cell Immunity to Influenza VirusR21AI153120 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SWAIN, SUSAN L · 2020 to 2021
$461k
Control of CD4 T cell effector function and tissue-resident memory fate by the transcription factor EomesR21AI146647 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI MCKINSTRY, KARL KAI · 2019 to 2020
$410k
Memory CD4 T Cell Regulation of Innate Lymphoid CellsR21AI117457 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI STRUTT, TARA MARLENE · 2016 to 2017
$379k
NIAID NIH HHS R01 AI118820NIAID NIH HHS R01 AI143976NIAID NIH HHS R01 AI165406NIAID NIH HHS R21 AI117457NIAID NIH HHS R21 AI146532NIAID NIH HHS R21 AI146647NIAID NIH HHS R21 AI153120NIAID NIH HHS R21 AI173593NIAID NIH HHS T32 AI007349NIAID NIH HHS T32 AI132152NIAID NIH HHS U19 AI109858
6 · The paper itself

Abstract

Initial TCR affinity for peptide Ag is known to impact the generation of memory; however, its contributions later, when effectors must again recognize Ag at 5-8 d postinfection to become memory, is unclear. We examined whether the effector TCR affinity for peptide at this "effector checkpoint" dictates the extent of memory and degree of protection against rechallenge. We made an influenza A virus nucleoprotein (NP)-specific TCR transgenic mouse strain, FluNP, and generated NP-peptide variants that are presented by MHC class II to bind to the FluNP TCR over a broad range of avidity. To evaluate the impact of avidity in vivo, we primed naive donor FluNP in influenza A virus-infected host mice, purified donor effectors at the checkpoint, and cotransferred them with the range of peptides pulsed on activated APCs into second uninfected hosts. Higher-avidity peptides yielded higher numbers of FluNP memory cells in spleen and most dramatically in lung and draining lymph nodes and induced better protection against lethal influenza infection. Avidity determined memory cell number, not cytokine profile, and already impacted donor cell number within several days of transfer. We previously found that autocrine IL-2 production at the checkpoint prevents default effector apoptosis and supports memory formation. Here, we find that peptide avidity determines the level of IL-2 produced by these effectors and that IL-2Rα expression by the APCs enhances memory formation, suggesting that transpresentation of IL-2 by APCs further amplifies IL-2 availability. Secondary memory generation was also avidity dependent. We propose that this regulatory pathway selects CD4 effectors of highest affinity to progress to memory.

Indexed as

CD4-Positive T-LymphocytesInterleukin-2AnimalsImmunologic MemoryMiceMice, Inbred C57BLMice, TransgenicPeptidesReceptors, Antigen, T-CellInterleukin-2PeptidesReceptors, Antigen, T-Cell

Identifiers

PMID37093656
PMCPMC10247507
OpenAlexW4366820621

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.